Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis ...
Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission ...
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1- At lower doses, patients maintained the improvem ...
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete ...
Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.
Increased esophageal hypervigilance and anxiety were associated with worse post-treatment symptoms and poor quality of life ...
We read with interest the article by Santacroce about personalised medicine in eosinophilic oesophagitis (EoE) and the identification of novel therapeutic targets.1 While dietary approaches are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback